Research reveals a hidden vulnerability of lung cancer

Research reveals a hidden vulnerability of lung cancer

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to a preclinical study led by Roswell Park Comprehensive Cancer Center. Results of the study, led by Sayan Chakraborty, Ph.D., Assistant Professor of Oncology, Department of Pharmacology & Therapeutics at Roswell Park, have been published in the journal Advanced Science.

Tomasi revived basic and clinical research at Roswell Park - The Cancer Letter

Dr. Thomas B. Tomasi, Jr. president and CEO of Roswell Park Comprehensive Cancer Center from 1986 to 1996, died on March 23. He was 97. Dr. Tomasi came to Roswell in the mid-80s, at a time when the leadership was stagnant, and the future of the hospital and its very mission were in question. Tom and his team brought transformative ideas to the institute, reviving the importance of both basic and clinical research and its connection to excellence…